Drugs / VG2025
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06365918 | Sep → Oct 2024 | metastatic carcinoma | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 1 | NCT05266612 | Nov 2022 → Dec 2024 overdue | neoplasm | Virogin Biotech Canada Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT05477849 | Aug 2022 → Oct 2025 overdue | cancer | Virogin Biotech Ltd. | Recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07682870 | Sep 2026 → Dec 2028 expected | cancer | Virogin Biotech Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07357220 | Mar 2026 → Feb 2027 expected | metastasis from malignant tumor of colon | Akeso | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07522476 | Jul 2026 → Jan 2028 expected | intrahepatic cholangiocarcinoma | Virogin Biotech Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VG2025 | “VG2025 is a Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection.” NCT05477849 ↗5“VG2025 is a Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection.” NCT07682870 ↗ |
| Route | Other | “VG2025, administered as intratumoral injections” NCT05266612 ↗ |